
Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis

ABSTRACT

For many years, small but significant advancements have been made time and again in the prevention and treatment of early breast cancer. The so-called panel gene analyses are becoming more and more important in prevention, since the risk due to the tested genes is better understood and as a result, concepts for integration in health care can be developed. In the adjuvant situation, the first study in the so-called post-
neoadjuvant situation was able to demonstrate a clear improvement in the prognosis with an absent pathological complete remission following trastuzumab or pertuzumab + trastuzumab. Additional studies with this post-neoadjuvant therapeutic concept are still being conducted at present. The CDK4/6 inhibitors which had shown a significant improvement in progression-free survival in a metastatic situation are currently being tested in the adjuvant situation in large therapeutic studies. These and other new data for the treatment or prevention of primary breast cancer are presented in this review against the backdrop of current studies.

**ZUSAMMENFASSUNG**


**Introduction**

The prognosis of primary early breast cancer has continued to improve in the past few decades. This is seen in the improvement in the 5-year survival as well as in the increase in the rates of pathological complete remission (pCR) within the scope of neoadjuvant therapy concepts [1, 2]. This suggests that not only optimisation of local therapy or early detection [3, 4] improved prognosis but also systemic therapy. The introduction of new substances and therapeutic regimens was able to improve therapy in the (neo)adjuvant situation little by little [5–7]. The choice of patient population appears to play an ever more important role here. For example, some years ago, so-called post-neoadjuvant studies were initiated which continued to treat patients who had not reached complete remission following neoadjuvant therapy. This type of study in particular appears to play an important role nonetheless, because they investigate a specific resistance population. This therapy concept but also aspects of prevention, surgical treatment, radiation therapy and other treatment strategies are discussed in this review.

**Prevention and Risk Factors**

Nearly 25 years after the discovery of **BRCA1** and **BRCA2**, the techniques for genotyping have developed considerably further while the costs have decreased. Nowadays, when testing for risk genes in the genome, it is no longer only **BRCA1** and **BRCA2** which are genotyped, but rather a number of other genes which also influence the breast cancer risk. These are generally other genes which, in the case of a mutation, are also associated either with a disease risk similarly high as that of **BRCA1** or **BRCA2** or those genes which lead to a moderate disease risk [8–10].

Various works have reported on the mutation frequencies or risks in comparison to healthy control persons [11–17]. One of the genes which was discussed as being classified either in the high-risk group (similar to **BRCA1** and **BRCA2**) or in the group with a medium disease risk is **PALB2** [11, 12]. Initial studies had estimated the lifetime risk between 35 and 55% [11,18]. Another large study which analysed the extensive panel gene analyses on approx. 20000 cases of breast cancer and 20000 health control persons has now been published [19]. This study describes the relative risks for **BRCA1** and **BRCA2** with values of 7.9 and 6.7 and shows a relative risk of 4.8 for **PALB2**. Other genes identified with statistical significance were **CHEK2** and **ATM** with relative risks of 2.5 and 1.7. If the cases were limited to the triple-negative patients, odds ratios of approx. 40 for **BRCA1**, approx. 14 for **PALB2** and approx. 9 for **BRCA2** [19] were seen. In clinical practice, lifetime risks are more helpful than relative risks. The corresponding lifetime risks were calculated at 50–55% for **BRCA1** and **BRCA2**. **PALB2** followed at slightly below 35%. **CHEK2** and **ATM** were below this figure, at 25 and 15% [19]. The lifetime risks appear to be high enough in order to discuss individual risk-reducing measures, however they are not the only genetic factors known to increase the risk of breast cancer. The high-grade and medium-grade penetrant risk genes explain about 20% of the familial risk for breast cancer, while low penetrant but frequent genetic variants in over 170 loci explain a further 16% of the familial breast cancer risk [8, 20–27]. In order to also possibly harness these low penetrant risk variants for an individual risk determination, a risk score with 77 gene loci has already been previously developed [28]. This has now been supplemented with additional risk genes and redeveloped with 313 gene loci. Women in the highest percentile had a lifetime risk of approx. 33% (▶ Fig. 1) which can by all means be relevant for individual counselling [29]. For women around 60 years of age, a 10-year disease risk of more than 10% can be calculated [29]. As in the case of all risk calculations, the identification of women with a risk for breast cancer with a poor prognosis is important. It was shown here that the polygenetic risk score in particular predicted the risk for hormone-receptor-positive carcinomas. While the lifetime risk for hormone-receptor-positive carcinomas could be calculated at over 30%, the corresponding lifetime risk for hormone-receptor-negative carcinomas was approx. 4% [29]. The genes which account for a subtype-specific risk
are known in part [15, 22, 30–39] and are of particular interest for the development of individualised preventative measures.

The additional combination with other risk factors could entail a further improvement in the risk prediction, since it is known that non-genetic risk factors have subtype-specific effects on the risk [40] and the polygenetic risk score either interacts with other risk factors or non-genetic risk factors improve the risk prediction in addition to the risk score [41–43].

Surgical Treatment

This year, a panel of experts published a needs assessment which identified the fields in which a special focus should be scientifically placed in the area of breast surgery in the near future. The important objectives of the further development are shown in Table 1: A roadmap for research needs in breast surgery at the current time [44]. For some of the issues raised in the report, there were interesting findings this year on which future research approaches can be built.

Between 2006 and 2016, the Young Women’s Breast Cancer Study [45] which was conducted in the USA, included a total of 1302 women aged 40 with invasive breast cancer, 317 of whom received neoadjuvant therapy. Pretherapeutically, only 85 patients (27%) were judged to be candidates for breast-conserving therapy. Posttherapeutically, this figure increased to 163

(51%). Only 80 of these patients (49%) opted for breast-conserving therapy, 83 (51%) chose mastectomy. The two most important reasons for a mastectomy were patient preference (46%)

Table 1 Important objectives on the further development of breast surgery (acc. to [44]).

<table>
<thead>
<tr>
<th>Diagnosis and assessment</th>
<th>Neoadjuvant therapy</th>
<th>Surgical management</th>
<th>Special groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Addressing overdiagnosis and overtreatment, particularly in the context of screening</td>
<td>• Understanding which patients will benefit most from treatment with neoadjuvant chemotherapy or endocrine therapy, how this benefit differs by biological subtypes, and what biomarkers can best guide decision making (eg. through window-of-opportunity studies)</td>
<td>• Developing strategies to reduce the rates of re-excision for patients undergoing breast conserving surgery through developments in localisation techniques and intraoperative margin assessment methods</td>
<td>• Defining and standardising indications for risk-reducing surgery and understanding the long-term outcomes of bilateral mastectomy for those who are considered at high risk</td>
</tr>
<tr>
<td>• Understanding the biology, importance, and long-term outcomes of intermediate (83) lesions and ductal carcinoma in situ</td>
<td>• Identifying the optimal treatment choice and sequencing</td>
<td>• Understanding the role of alternatives to surgical excision. Assessment of clinical and cost-effectiveness of oncoplastic and reconstructive surgery using standardised measures and how this is affected by patient factors and adjuvant treatment, particularly adjuvant radiotherapy to the chest wall</td>
<td>• Defining and standardising indications for contralateral mastectomy in those with previous cancer to optimise benefits and minimise harm</td>
</tr>
<tr>
<td>• Understand the biological significance and optimal therapeutic strategies for additional foci of previously subclinical disease detected with advanced imaging techniques</td>
<td>• Understanding the long-term outcomes of neoadjuvant endocrine therapy</td>
<td>• Robust evaluation of novel procedures and techniques using standardised measures and commitment of the surgical community to the concept of no innovation without evaluation</td>
<td>• Increased understanding of breast cancer and differing patient needs in specific groups, including patients younger than 40 years, older patients, men, and patients with pregnancy-associated breast cancer</td>
</tr>
<tr>
<td>• Finding the best model for symptomatic assessment that allows rapid, patient-centred, and cost-effective evaluation, while maintaining diagnostic accuracy</td>
<td>• Identifying the optimal modalities (radiological and biomarker) for monitoring treatment response</td>
<td>• Further study of survivorship, including optimisation of follow-up, secondary prevention, and the role of surgery for treatment-related morbidity, such as lymphoedema</td>
<td>• Understanding the role of surgery for metastatic disease</td>
</tr>
<tr>
<td>• Establishing how and when to stage for distant disease and how best to monitor for relapse</td>
<td>• Optimising rates of breast conserving surgery after neoadjuvant treatment</td>
<td>• Management of the axilla in patients undergoing neoadjuvant therapy, particularly those who convert from node-positive to node-negative disease during treatment and the role of sentinel lymph node biopsy after treatment</td>
<td></td>
</tr>
</tbody>
</table>
and/or a BRCA1/2 or TP53 mutation (37%). Of the 75 patients (24%) who achieved pCR, 48 (64%) received a mastectomy and only 21 of them 21 (44%) for anatomical reasons (inflammatory carcinoma, extensive intraductal components, etc.) [45]. These data show that, especially in young patients, the decision for or against a mastectomy after neoadjuvant therapy is often made more for personal and risk-reduction reasons than for strictly oncological reasons. Whether these results can be transferred to other care structures, such as in Germany, has not yet been investigated to date.

In this context, reference should be made to the results of two other studies, each with far more than 500 patients and which addressed with the long-term quality of life following breast cancer surgery: the E5103 study [46] which had included all age groups, and another large multicentre study which assessed quality of life (QoL) in patients under age 40 [47]. In both investigations, the authors found indications that the long-term quality of life was negatively affected by the radical nature of the surgical approach. In particular in the investigation which had included patients under age 40 (range 26–40, mean age 37 years), the psychosocial and sexual well-being was significantly worse in the group of patients who underwent mastectomy [46, 47]. It is known from other studies that dissatisfaction with the outcome following a mastectomy without reconstruction persists for many years [48]. Such data must be continuously reviewed in light of modern and less traumatising reconstruction techniques; however, they should also be mentioned within the context of informed consent during preoperative counselling.

Several translational analyses of the SENTINA study [49] were presented this year on the question of management of the axilla following neoadjuvant chemotherapy. In one investigation, the post-therapeutic involvement of axillary lymph nodes in the case of affected sentinel lymph nodes prior to neoadjuvant therapy was analysed. 71 out of 318 patients (22.3%) still had affected lymph nodes following neoadjuvant therapy, whereby patients with a positive HER2 status and a negative axillary status had the highest pCR rates of the breast [50]. In another analysis as well in which a normogram for the prediction of nodal conversion was developed for patients under age 40 [47]. It is known from other studies that dissatisfaction with the outcome following a mastectomy without reconstruction persists for many years [48]. Such data must be continuously reviewed in light of modern and less traumatising reconstruction techniques; however, they should also be mentioned within the context of informed consent during preoperative counselling.

The sentinel lymph node biopsy (SNB) is the standard in clinically unremarkable axillary lymph nodes. However, what should be done if these lymph nodes are affected by tumour? The ACOSOG0011 study showed that dispensing with a further axillary lymphadenectomy (ALND) does not lead to an increased rate of recurrence, although 23% of patients have other affected lymph nodes which remain in situ. The main critical points of the study were the low statistical power (discontinuation due to low recruitment) and the unclear irradiation fields at the axilla [52].

The main question of the AMAROS study (n = 1425) [53] was more clearly defined here: in the event of a positive SNB, should irradiation (AxRT) or surgery (ALND) be performed? After 10 years of follow-up, a very low rate of local recurrence in both arms was seen overall, although additional metastases were found in the surgical arm in 32.8% of patients. The rate of axillary recurrence was 1.82% in the AxRT arm and 0.93% in the ALND arm (HR 1.71; 95% CI: 0.67–4.39, p = 0.365). In DFS as well, there was no difference (HR 1.19; 95% CI: 0.97–1.45). However, the rate of lymphoedema requiring treatment was significantly higher in the ALND arm. 82% of the patients received breast-conserving surgery and 17% underwent mastectomy and thus the results for both collectives appear representatives with a very low event rate, however. Conclusion: If axilla is clinically unremarkable and despite affected sentinel lymph nodes, further surgery is not felt to be appropriate. Whether extensive (AMAROS) or tangential (ACOSOG0011) irradiation should be performed cannot be answered yet [53].

Partial breast irradiation

In radiation therapy as well, de-escalation is an important strategy for reducing therapy-related morbidity and/or the duration of treatment. Partial breast irradiation by means of interstitial brachytherapy, three-dimensional conformal external irradiation or intraoperative irradiation (e.g. Intrabeam®) could contribute to this. Within the scope of the randomised phase III study NSABP B-39, which included a total of 4216 patients with primary breast cancer in stage I–III, the non-inferiority of partial breast irradiation versus conventional whole-breast irradiation was investigated [54]. All forms of partial breast irradiation were permitted. The ipsilateral rate of recurrence was selected as the primary endpoint of the study. The mean follow-up was 10.2 years. The non-inferiority unfortunately could not be demonstrated, even though the 10-year rate of recurrence in the case of partial breast irradiation was only 0.7% higher (4.6 vs. 3.9%). The recurrence-free interval in the case of partial breast irradiation was in fact significantly shorter (recurrence-free 10-year interval 91.8 vs. 93.4%), however no difference was seen in the case of metastasis- and disease-free survival or overall survival. The grade 3–5 rates of toxicity do not differ significantly. Thus for the low-risk patients, partial breast irradiation may represent an option due to the only slightly increased risk of recurrence versus whole-breast irradiation.

Irradiation of the lymphatic vessels

The indication for irradiation of the lymphatic drainage area (LDA) is based on the current guidelines and therapeutic recommendations for the involvement of more than three lymph nodes (LN), independent of the size of the tumour as well as high-risk constellations (1–3 LNs affected, G2–3, ER/PR negative) [55–57]. A current meta-analysis which altogether included data from 13500 patients from 14 studies, confirmed this approach [58]. While earlier studies from 1961–1978 showed a slightly improved breast cancer mortality (–0.5%) and had an increased overall mortality, the more recent studies from 1989 and later demonstrated a significantly reduced breast cancer and overall mortality (–2.8% and
~ 2.9%). This can most likely be attributed to precision radiation therapy which minimises the cardiac radiation exposure (below 8 Gy). In the subgroup evaluation, patients with more than three affected LNs particularly benefited from irradiation of the LDA. Thus the meta-analysis confirms the currently recommended approach.

Therapy for Primary Triple-Negative Breast Cancer

The treatment of triple-negative breast cancer (TNBC) in the adjuvant or neoadjuvant situation is marked by the fact that chemotherapy demonstrates good efficacy in a portion of the patients and this results in a considerable improvement in the prognosis. Thus it was able to be shown in neoadjuvant studies that triple-negative patients who achieve pCR have an excellent prognosis, similarly to HER2-positive patients [59–66].

In the event of a lack of pCR following neoadjuvant chemotherapy, the CREATE-X study examined an adjuvant therapy with capecitabine in HER2-negative patients [67]. Particularly in the triple-negative patients, this study, which was conducted in Asia, showed an advantage for disease-free survival (DFS) with a hazard ratio of 0.59 (95% CI: 0.39–0.87) [68]. The CREATE-X study examined an adjuvant therapy with capecitabine in HER2-negative patients [67]. Particularly in the triple-negative patients, this study, which was conducted in Asia, showed an advantage for disease-free survival (DFS) with a hazard ratio of 0.59 (95% CI: 0.39–0.87) [68]. The CREATE-X study examined an adjuvant therapy with capecitabine in HER2-negative patients [67]. Particularly in the triple-negative patients, this study, which was conducted in Asia, showed an advantage for disease-free survival (DFS) with a hazard ratio of 0.59 (95% CI: 0.39–0.87) [68]. The CREATE-X study examined an adjuvant therapy with capecitabine in HER2-negative patients [67]. Particularly in the triple-negative patients, this study, which was conducted in Asia, showed an advantage for disease-free survival (DFS) with a hazard ratio of 0.59 (95% CI: 0.39–0.87) [68].

The CIBOMA/2004-01_GEICAM/2003-11 study was conducted in a different study setting but with the same question regarding modified therapy [69]. This study, which was conducted in Spain and Latin America, admitted triple-negative patients following adjuvant or neoadjuvant chemotherapy who received further treatment after completing therapy with capecitabine or who did not receive any further therapy. As expected, the toxicity in the experimental arm was higher. In addition, no improved, recurrence-free survival could be observed (HR: 0.82 [95% CI: 0.63, 1.06], p = 0.136). A difference could be detected only in a subgroup with non-basal TNBC carcinomas (EGFR and CK5/6 negative) (p = 0.020, HR: 0.53 [95% CI: 0.31, 0.91]). However, since the study was negative overall, it was also concluded in the subsequent discussion that, outside of the conditions in the Create-X study, the use of capecitabine is not indicated in patients with TNBC [69].

In some studies, the efficacy of gemcitabine, nab-paclitaxel and carboplatin in early breast cancer has already been investigated [70–81]. In summary, these studies showed that the addition of gemcitabine to standard therapy did not lead to any improvement and the latter yielded a benefit in a comparison between standard therapy and therapy containing platinum. In the ADAPT study, a higher pCR rate (26 vs. 45%) in patients with therapy containing platinum could be found [82] in triple-negative patients following neoadjuvant chemotherapy in a comparison between treatment with nab-paclitaxel and gemcitabine vs. nab-paclitaxel and carboplatin [82]. With regard to disease-free survival (DFS), the study did not find any difference in the two treatment arms [83]. The question of possible predictive markers was posed in a recently presented analysis [84]. While patients with pCR and higher PD1 expression had the best prognosis, no predictive markers for the superiority of carboplatin in TNBC in neoadjuvant chemotherapy were able to be identified. In patients with pCR after 12 weeks and a high baseline PD1 (mRNA), the post-operative continuation of chemotherapy with 4 cycles of epirubicin and cyclophosphamide did not lead to a better prognosis. However, the decision regarding continuation of the neoadjuvant therapy was not randomised. The authors evaluated this as an indication for a possible future basis for de-escalation, even if the results currently only generate hypotheses and cannot be assessed as the current basis for decision-making [84].

Adjuvant Therapy of Primary, Hormone-Receptor-Positive, HER2-negative Breast Cancer

There are primarily three questions associated to date with the therapy of hormone-receptor-positive, HER2-negative breast cancer patient in the adjuvant situation: In which risk constellation must chemotherapy be administered? What is the optimal anti-endocrine therapy? And how long should this be given?

With regard to the question of chemotherapy, it is known that patients with a positive hormone receptor status, particularly with low proliferation, do not respond well to chemotherapy [60, 62, 85]. The question thus arises as to whether chemotherapy is of any use at all in such a patient population. The TAILOR-X study recently showed that patients who had achieved an intermediate score with regard to the risk of relapse in a multi-gen assay do not benefit from adjuvant chemotherapy followed by anthrnonal therapy in comparison to antihormonal therapy alone [86]. Thus in this patient population, chemotherapy could be omitted. Newly presented quality-of-life data from the TAILOR-X study highlight this therapeutic decision approach [87] (further discussion in [88]).

In the question regarding the length of the adjuvant, antihormonal therapy with aromatase inhibitors, therapy until the 10th year after diagnosis is recommended to date in the guidelines and therapeutic recommendations more for patients with an increased risk of relapse than for patients with a low risk of relapse. The numbers of cases for such analyses were relatively small in the respective studies, however. The question also arises as to whether expanded adjuvant therapy with an aromatase inhibitor after tamoxifen brings as much benefit as after an aromatase inhibitor. These questions were addressed by a meta-analysis of the Early Breast Cancer Trialists Collaborative Group with more than 22,000 patients from 11 studies [89].

The very comprehensive analyses investigated, on the one hand, the effect of aromatase inhibitors after 5 years of tamoxifen, after 5 years of aromatase inhibitors or after 5–10 years of a sequence of tamoxifen and aromatase inhibitors. In addition, subgroup analyses were performed in the overall population for patients with 0, 1–3 and more than 3 affected lymph nodes. The therapeutic effect was the greatest in the group of patients who were pretreated only with tamoxifen and only marginal for patients who had received five years of pretherapy with aromatase inhibitors. The relative risks for all analyses are shown in Table 2. In the analysis of the relative risks for a recurrence as a function of the node status, it was shown that the greatest effect could be
seen in the population of patients who had more affected lymph nodes at primary diagnosis (Table 2) [89]. It is also important to note that the risk of bone fractures due to the expanded AI therapy was increased by 24% [89].

In a similar context, the AERAS study presented by Ohtani et al. is noteworthy: The expanded therapy with anastrozole for a total of 10 years in 840 patients reduced the DFS events by half in comparison to 843 patients whose endocrine therapy was ended after 5 years (HR 0.548, p = 0.0004). No influence on overall survival was able to be shown. At the same time, the fracture rate of 2.8% in the expanded therapy arm was twice as high as in the control arm (1.1%) [90].

Another option for intensifying the adjuvant endocrine therapy is to combine the endocrine therapy with substances which have already shown in a metastatic situation that they can overcome endocrine resistance in at least some patients. After the introduction of everolimus in the treatment of patients with metastatic breast cancer [91,92], adjuvant studies were also subsequently started (e.g. NCT01674140, NCT01805271); they are still awaiting publication. Another option is the combination with CDK4/6 inhibitors which have a more favourable adverse effect profile. In this regard, there were recently meaningful results from the neoadjuvant endocrine therapy situation. Dowsett et al. presented the results from the Pallet study: In this study, palbociclib was given in addition to three months of neoadjuvant endocrine therapy with letrozole. It was shown that the antiproliferative effect of the aromatase inhibitor is substantially increased by palbociclib: The percentage of tumours which underwent a complete cell cycle arrest in the form of a Ki-67 value < 2.7% during neoadjuvant therapy was able to be increased through the addition of palbociclib from 58.5 to 90.4% [93].

With new, effective combination therapies, additional options are available which increasingly improve the adjuvant therapy of the hormone-receptor-positive, HER2-negative patient. At present, adjuvant therapy studies are being conducted for all CDK4/6 inhibitors (Penepele, PALLAS, MonarchE and NataLEE).

With the further development of adjuvant antihormonal therapy, the question of compliance arises, particularly in the case of an adverse effect profile known to be more unfavourable, and this question has already been discussed in the adjuvant studies with an antiendocrine monotherapy. Some studies have reported on adherence [94 – 98], which was between 60 and 90%. It will be of interest to see how this is influenced by combination with a CDK4/6 inhibitor, particularly as it is known that adverse effects are one of the main predictors for non-adherence.

### Therapy of Primary HER2-positive Breast Cancer

#### Benefits of neoadjuvant therapy

Neoadjuvant systemic therapy permits in-vivo sensitivity testing in addition to a reduction in surgical morbidity (more breast conservation, fewer axillary lymphadenectomies) [99,100]. Based on the effect of the neoadjuvant systemic therapy on the primary tumour, its effect on the long-term prognosis can be estimated, possibly through the destruction and monitoring of micrometastases [62,101].

A recent meta-analysis once again highlighted the prognostic significance of reaching pathological complete remission (pCR) following neoadjuvant chemotherapy [102]. After evaluating 52 studies (51.1% randomised; 61.1% single-arm; 42.8% retrospective) with 27 895 patients and a median follow-up period of 4 years, it was confirmed that, by achieving pCR, the risk of a breast cancer event decreases significantly by 69% (HR 0.31; 95% CI 0.24–0.39) and the risk of dying decreases significantly by 78% (HR 0.22; 95% CI 0.15–1.30). The absolute effect after 5 years on DFS and overall survival (OS) was 21 and 19%, respectively (Fig. 2 and 3). With a short follow-up time, the absolute effect was the greatest in the case of patients with triple-negative breast cancer, followed by patients with HER2-positive and hormone-receptor-positive, HER2-negative breast cancer (Δ in the 5-year DFS 33 vs. 23 vs. 9%). According to the statistics, a Δ in the pCR rate of 20% transferred in the studies into a reduction in the event risk by approx. 20% [102]. Additional postoperative chemotherapy after reaching pCR did not improve the prognosis.

### Table 2 Risk reductions of expanded antihormonal therapy with aromatase inhibitors (AI) after tamoxifen (TAM), AI or TAM, followed by AI (according to [89]).

<table>
<thead>
<tr>
<th>Prior therapy</th>
<th>n</th>
<th>Any relapse RR (95% CI)</th>
<th>p value</th>
<th>Distant metastases RR (95% CI)</th>
<th>p value</th>
<th>Breast cancer mortality RR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 years TAM</td>
<td>7483</td>
<td>0.67 (0.57–0.79)</td>
<td>&lt;0.00001</td>
<td>0.77 (0.63–0.93)</td>
<td>0.008</td>
<td>0.77 (0.59–1.00)</td>
<td>0.05</td>
</tr>
<tr>
<td>5 years AI</td>
<td>3322</td>
<td>0.76 (0.61–0.95)</td>
<td>0.2</td>
<td>0.78 (0.59–1.04)</td>
<td>0.09</td>
<td>0.99 (0.68–1.44)</td>
<td>0.97</td>
</tr>
<tr>
<td>5–10 years Tam, then AI</td>
<td>11387</td>
<td>0.82 (0.73–0.93)</td>
<td>0.002</td>
<td>0.92 (0.80–1.07)</td>
<td>0.29</td>
<td>0.93 (0.77–1.12)</td>
<td>0.45</td>
</tr>
<tr>
<td>All patients</td>
<td>22192</td>
<td>0.76 (0.70–0.83)</td>
<td>&lt;0.00001</td>
<td>0.85 (0.77–0.95)</td>
<td>0.004</td>
<td>0.89 (0.77–1.02)</td>
<td>0.09</td>
</tr>
<tr>
<td>Pat. with N0</td>
<td>10620</td>
<td>0.82 (0.71–0.95)</td>
<td>0.009</td>
<td>–1</td>
<td>–1</td>
<td>–1</td>
<td>–1</td>
</tr>
<tr>
<td>Pat. with 1–3 LN</td>
<td>6919</td>
<td>0.74 (0.64–0.85)</td>
<td>0.00003</td>
<td>–1</td>
<td>–1</td>
<td>–1</td>
<td>–1</td>
</tr>
<tr>
<td>Pat. with &gt;3 LN</td>
<td>1621</td>
<td>0.71 (0.56–0.89)</td>
<td>0.003</td>
<td>–1</td>
<td>–1</td>
<td>–1</td>
<td>–1</td>
</tr>
</tbody>
</table>

1 not reported
Improvement in prognosis through a switch to T-DM1 in the case of non-pCR

The phase III CREATE X study showed for the first time that, by adapting the postoperative therapy to the pathological response to the neoadjuvant therapy, the risk of recurrence and mortality can be significantly decreased [67]. While the CREATE X study included only patients with a HER2-negative breast cancer who did not achieve pCR through neoadjuvant chemotherapy, the KATHERINE study tested the same approach in patients with HER2-positive breast cancer [103,104]. This study included 1486 patients with primary HER2-positive breast cancer who had not achieved pCR following neoadjuvant standard therapy with at least one taxane and trastuzumab for at least 9 weeks. The neoadjuvant therapy could include anthracyclines and a dual anti-HER2 blockade. The patients were randomised postoperatively and received either trastuzumab emtansine (T-DM1) 3.6 mg/kg or trastuzumab 6 mg/kg every 3 weeks for 14 cycles, at the same time as locoregional and, in the case of hormone receptor expression, endocrine standard therapy. Prospective stratification was performed according to operability (primarily operable vs. inoperable), hormone receptor status (positive vs. negative), type of neoadjuvant anti-HER2 therapy (trastuzumab vs. dual blockade with trastuzumab and pertuzumab) and the nodal status following surgery (ypN0 vs. ypN+). With a median follow-up period of 41 months, the switch to T-DM1 significantly improved the primary endpoint, the invasive disease-free survival after 3 years (IDFS), from 77.0 to 88.3% (Δ11.3%; HR 0.50; 95% CI 0.39–0.64; p < 0.0001) (▶ Fig. 4). The relative effect was the same in all stratified subgroups, particularly also in the case of patients with a very small residual tumour (≤ ypT1b ypN0) and in those who had neoadjuvantly received a dual anti-HER2 blockade. This also appears to be important to mention for this reason, because the neoadjuvant therapy with trastuzumab and pertuzumab, similar as in clinical studies, had also shown a higher pCR rate in real-world analyses [105].

The metastasis-free survival (distant disease-free survival, DDFS) after 3 years was also significantly improved from 83.0 to 89.7% (Δ6.7%; HR 0.60; 95% CI 0.45–0.79). This benefit was achieved at the expense of a clinically easily controlled increase in thrombopenia (grade ≥ 3 Δ5.7%), increased liver values (grade ≥ 3 Δ approx. 1%) and polyneuropathy (grade ≥ 3 Δ 1.4%) [103]. Thus the switch to T-DM1 in the case of non-pCR following adequate neoadjuvant systemic therapy in HER2-positive primary breast cancer represents a new therapeutic standard.

Duration of the trastuzumab treatment

In patients with HER2-positive, primary breast cancer who are indicated for treatment with trastuzumab, the question repeatedly arises as to whether a one-year treatment duration is absolutely necessary or whether shorter therapy can be considered [106]. In this context, the final survival data from the phase III PHARE study were recently presented [107]. In this non-inferiority study, 3384 patients with HER2-positive, primary breast cancer (57.7% hormone-receptor-positive; 44.6% nodal-positive; approx. 43% trastuzumab therapy sequentially) who were still event-free after 6 months on trastuzumab randomly received either trastuzumab for another 6 months or no further anti-HER2 therapy. With a median follow-up time of 7.5 years, the DFS as well as the DDFS and OS after only 6 months of trastuzumab therapy were not clearly equally good as after one year of trastuzumab. The upper limit of the 95% CI of the HR was above the predefined maximum value of 1.15. However, in the subgroup in which trastuzumab was already started during chemotherapy, both therapy arms were equally effective. Nevertheless, the equivalence of 6 vs. 12 months of trastuzumab treatment could not be demonstrated with sufficient certainty overall and thus trastuzumab therapy for a year remains the standard.

---

**Fig. 2** Event-free 5-year probability after neoadjuvant chemotherapy and with pathological complete remission (blue) or without pCR (red).

**Fig. 3** 5-year overall probability after neoadjuvant chemotherapy and with pathological complete remission (blue) or without pCR (red).
Outlook

With the KATHERINE study, a large adjuvant study which can demonstrate a significant reduction in the risk of relapse for the HER2-positive patient population treated neoadjuvantly was presented. This is significant not only for this patient group but also for patients with other tumour biologies. Patients with hormone-receptor-positive, HER2-negative breast cancer were treated in a similar, post-neoadjuvant therapy concept with palbociclib. The initial results are expected in mid-2019. The Olympia study also included post-neoadjuvant patients with a BRCA mutation for therapy with olaparib.

Independent of the post-neoadjuvant situation, three large adjuvant studies with CDK4/6 inhibitors which also have a potential for significant therapeutic efficacy are currently being conducted.

Acknowledgements

This work was developed in part as a result of support from Riemser and the PRAEGNANT network which is supported by Hexal, Pfizer, Celgene, Daiichi-Sankyo, Roche, Merrimack, Eisai, and Novartis. None of the companies played a role in the drafting of this manuscript. The authors alone are responsible for the content of the manuscript.

Conflict of Interest

A. D. H. received speaker and consultancy honoraria from AstraZeneca, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi-Sankyo, Hexal and Pfizer. N. N. received consultancy honoraria from Janssen-Cilag and Novartis. F. O. received speaker and consultancy honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Chugai, Celgene, Cellex, Eisai, Gilead, Hexal, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Riemser, Roche, Tesaro, Teva. F.-A. T. received honoraria from Astra Zeneca, Genomic Health and Novartis. H.-C. K. received honoraria from Carl Zeiss meditec, Teva, Theraclear, Novartis, Amgen, Astra Zeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche and Genomic Health. P. A. F. received honoraria from Novartis, Pfizer, Roche, Amgen, Celgene, Daiichi-Sankyo, AstraZeneca, Merck-Sharp & Dohme, Eisai, Puma and Teva. His institution conducts research with funding from Novartis and Biontech. H. T. received honoraria from Novartis, Roche, Celgene, Teva, Pfizer and travel support from Roche, Celgene and Pfizer. J. E. received honoraria from Astra Zeneca, Roche, Celgene, Novartis, Lilly, Pfizer, Pierre Fabre, Teva and travel support from Celgene, Pfizer, Teva and Pierre Fabre. M. P. L. has participated on advisory boards for AstraZeneca, MSD, Novartis, Pfizer, Eisai, Genomic Health and Roche and has received honoraria for lectures from MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, AstraZeneca, medac and Eisai. V. M. received speaker honoraria from Amgen, Astra Zeneca, Celgene, Daiichi-Sankyo, Eisai, Pfizer, Novartis, Roche, Teva, Janssen-Cilag and consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, Novartis, MSD, Daiichi-Sankyo and Eisai, Lilly, Tesaro and Nektar. E. B. received honoraria from Novartis, Celgene, Riemser, Pfizer, Hexal, Amgen, and onkowissen.de for consulting, clinical research management or medical education activities. A. S. received honoraria from Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckschwerdt Verlag
References


[52] Giulano AE, Hunt KK, Ballman KV et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305: 569–575

[53] Rutgers EJ, Donker M, Poncet C et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: 10 year follow up results of the EORTC AMAROS trial (EORTC10981/22023). San Antonio Breast Cancer Symposium 2018; Abstr. GS4-01

[54] Vicini FA, Cecchini RS, White JR et al. Primary results of NSABP B-39/ RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. San Antonio Breast Cancer Symposium 2018; Abstr. GS4-02


[61] Fasching PA, Loibl S, Hu C et al. BRCA1/2 Mutations and Bevacizumab in Neoadjuvant Therapy of Early Stage Breast Cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials. San Antonio Breast Cancer Symposium 2018; Abstr. GS4-02


Geyer CE jr., Huang CS, Mano MS et al. Phase III study of trastuzumab emtansine (T-DM1) vs. trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE. San Antonio Breast Cancer Symposium 2018; Abstr. GS1-10


Pivot X, Romieu G, Debled M et al. PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. San Antonio Breast Cancer Symposium 2018; Abstr. GS2-07